PCM
RXRX icon

Pentwater Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Pentwater Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100,000
Closed -$765K – 134
2023
Q3 		$765K Buy
+100,000
New +$998K ﹤0.01% 104

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pentwater Capital Management's RXRX Position: Q1 2024 in Review

Pentwater Capital Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2024, closing a stake of 100,000 shares — an estimated $986K sold.

Pentwater Capital Management first reported a position in RXRX in Q2 2021 and held it in 11 quarters. The position peaked at $9.22M in Q2 2021. 249 funds tracked by Wall St. Rank hold RXRX as of Q1 2024.

  • Pentwater Capital Management reported no remaining Recursion Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Pentwater Capital Management sold 100,000 Recursion Pharmaceuticals shares in Q1 2024, an estimated $986K.
  • Pentwater Capital Management first reported a position in Recursion Pharmaceuticals in Q2 2021 and held it in 11 quarters.
  • Pentwater Capital Management's Recursion Pharmaceuticals position peaked at $9.22M in Q2 2021.
  • 249 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2024.

Based on Pentwater Capital Management's 13F filing for Q1 2024, filed 15 May 2024.